Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer

PURPOSE OF REVIEW: Metastatic breast cancer (MBC) remains a major clinical challenge, necessitating the development of innovative therapeutic strategies. Estrogen receptor (ER) degradation using proteolysis-targeting chimeras (PROTAC) has emerged as a promising approach for overcoming acquired resis...

Descripción completa

Detalles Bibliográficos
Autor principal: Grinshpun, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
BREAST CANCER: Edited by Giuseppe Curigliano
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566586/
https://www.ncbi.nlm.nih.gov/pubmed/37427531
http://dx.doi.org/10.1097/CCO.0000000000000972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566586/
https://www.ncbi.nlm.nih.gov/pubmed/37427531
http://dx.doi.org/10.1097/CCO.0000000000000972

Ejemplares similares